Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Influence of statin treatment in a cohort of patients admitted for COVID-19
Journal Information
Vol. 158. Issue 12.
Pages 586-595 (June 2022)
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 158. Issue 12.
Pages 586-595 (June 2022)
Original article
Influence of statin treatment in a cohort of patients admitted for COVID-19
Influencia del tratamiento con estatinas en una cohorte de pacientes ingresados por COVID-19
Visits
...
Juan R. Reya,
,1
, José Luis Merino Llorensa, Ángel Manuel Iniesta Manjavacasa, Sandra Ofelia Rosillo Rodrígueza, Sergio Castrejón-Castrejóna, Emilio Arbas-Redondoa, Isabel Dolores Poveda-Pinedoa, Daniel Tebar-Márqueza, Andrea Severo-Sáncheza, Borja Rivero-Santanaa, Víctor Juárez-Olmosa, Marcel Martínez-Cossiania, Antonio Buño-Sotob, Luis Gonzalez-Vallec, Alicia Herrero-Ambrosioc, Esteban López-de-Sáa, Juan Caro-Codóna,1
a Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
b Servicio de Análisis Clínicos, Hospital Universitario La Paz, Madrid, Spain
c Servicio de Farmacia Hospitalaria, Hospital Universitario La Paz, Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Additional material (3)
Abstract
Aims and objectives

Statins have been proposed as potentially useful agents for modulating the host response in COVID-19. However, solid evidence-based recommendations are still lacking. Our aim was to study the association between statin use and clinical outcomes in a large cohort of hospitalized patients with SARS-CoV-2 infection, as well as the specific consequences of chronic treatment withdrawal during hospital admission.

Material and methods

Retrospective observational study including 2191 hospitalized patients with confirmed SARS-CoV-2 infection.

Results

Mean age was 68.0±17.8 years and 597 (27.3%) patients died during follow-up. A total of 827 patients (37.7% of the whole sample), received chronic treatment with statins. Even though they underwent more frequent admissions in critical care units, chronic treatment with statins was not independently associated with all-cause mortality [HR 0.95 (0.72-1.25)]. During the whole hospital admission, 371 patients (16.9%) received at least one dose of statin. Although these patients had a significantly worse clinical profile, both treatment with statins during admission [HR 1.03 (0.78-1.35)] and withdrawal of chronic statin treatment [HR 1.01 (0.78-1.30)] showed a neutral effect in mortality. However, patients treated with statins presented more frequently hepatic cytolysis, rhabdomyolysis and thrombotic/hemorrhagic events.

Conclusions

In this large cohort of hospitalized COVID-19 patients, statins were not independently associated with all-cause mortality during follow-up. Clinically relevant statin-associated adverse effects should be carefully monitored during hospital admission.

Keywords:
Statins
COVID-19
Mortality
Morbidity
Adverse effects
Treatment with drawal
Resumen
Antecedentes y objetivos

Se ha especulado que las estatinas pueden ser de utilidad en el tratamiento de pacientes con COVID-19, pero no existen evidencias clínicas sólidas. El objetivo de este trabajo es conocer su utilidad en una cohorte de gran tamaño de pacientes hospitalizados por COVID-19, así como si su retirada se asocia con un peor pronóstico.

Material y métodos

Estudio retrospectivo observacional. Se incluyeron 2.191 pacientes hospitalizados con infección confirmada con SARS-CoV-2.

Resultados

La edad media fue de 68,0 ± 17,8 años y fallecieron un total de 597 (27,3%) pacientes. Un total de 827 pacientes (37,7% de la muestra) estaban tratados previamente con estatinas. Aunque precisaron con mayor frecuencia de ingreso en camas de críticos, dicho grupo terapéutico no resultó un factor predictor independiente de muerte en el seguimiento [HR 0,95 (0,72-1,25)]. Un total de 371 pacientes (16,9%) recibió al menos una dosis de estatina durante el ingreso. A pesar de ser una población con un perfil clínico más desfavorable, tanto su uso [HR 1,03 (0,78-1,35)] como la suspensión durante el ingreso en pacientes que las recibían crónicamente [HR 1,01 (0,78-1,30)] presentaron un efecto neutro en la mortalidad. No obstante, el grupo con estatinas desarrolló con mayor frecuencia datos de citolisis hepática, rabdomiolisis y más eventos trombóticos y hemorrágicos.

Conclusiones

En nuestra muestra, las estatinas no se asociaron de forma independiente a una menor mortalidad en pacientes con COVID-19. En aquellos pacientes que tengan indicación de recibirlas por su patología previa es necesario monitorizar estrechamente sus potenciales efectos adversos durante el ingreso hospitalario.

Palabras clave:
Estatinas
COVID-19
Mortalidad
Morbilidad
Efectos adversos
Retirada medicación

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
Supplemental materials
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos